The current status of the use of palonosetron

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

(2011) Kenjiro Aogi et al.   SUPPORTIVE CARE IN CANCER

Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study

(2011) C. Yavas et al.   SUPPORTIVE CARE IN CANCER

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

(2010) Rudolph M Navari   Future Oncology

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

(2010) Tobias Engel Ayer Botrel et al.   SUPPORTIVE CARE IN CANCER

Aprepitant

(2009) Monique P. Curran et al.   DRUGS

Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

(2009) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

(2009) Lijun Tan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY